NCT02125071View on ClinicalTrials.gov

Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Liver CirrhosisChronic Hepatitis B
Interventions
OTHER

Blood Sample Collection

Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.

Trial Locations (1)

137-701

The Catholic University, Seoul St Mary Hospital, Seoul

Sponsors

Collaborators (1)

Green Cross Corporation
All Listed Sponsors
collaborator

Green Cross Corporation

INDUSTRY

lead

Dong-Gu Kim

OTHER